Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: WYD who wrote (3756)	12/7/2000 3:06:23 PM
From: megazoo	Read Replies (1) \| Respond to of 5665

Need help from biotech-savvy on the following re: IMGN. Yahoo board on IMGN consists following message :http://messages.yahoo.com/bbs?.mm=FN&action=m&board=7076932&tid=imgn&sid=7076932&mid=42271 I thought IMGN is way ahead of anybody else wrt eliminating toxicity. Thanks.

To: WYD who wrote (3756)	12/7/2000 4:22:50 PM
From: Icebrg	Respond to of 5665

Scott, I don't think the ODAC meeting on December 13-14 will handle things like INDs. Their agenda seems to be the following (going slightly off-topic). Ice "On Dec. 13, the committee will discuss new drug application Femara (letrozole) Tablets, 2.5 mg, Novartis Pharmaceuticals Corp., indicated as first-line therapy in postmenopausal women with advanced breast cancer and histamine hydrochloride injection (1 mg/ml), Maxim Pharmaceuticals, Inc for adjunctive use with interleukin-2 (aldesleukin) in the treatment of adult patients with advanced metastatic melanoma that has metastasized to the liver. On Dec. 14, the committee will discuss Biologics license application, Campath, (alemtuzumab), IlexTM Oncology Services and Millenium Pharmaceuticals for the treatment of patients with chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy; and single patient exemptions to the use of nonapproved oncology drugs and biologics".